Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARC

Launched by ASAN MEDICAL CENTER · May 15, 2017

Keywords

ClinConnect Summary

Preoperative chemoradiation (CRT) with fluoropyrimidine (5-fluorouracil or capecitabine) is now regarded as a standard treatment option in patients with locally advanced resectable rectal cancer and pathologic response rates and tumor regression grades after preoperative CRT have been proved to be important prognostic factors for survival outcomes.

Several studies of preoperative CRT with fluoropyrimidines plus other agents, such as oxaliplatin, irinotecan, cetuximab, and bevacizumab, have been performed to improve pathologic response rates; however, they have failed to show improved resul...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * To be eligible for inclusion, each patient must fulfill each of the following criteria:
• • 1. Histologically confirmed adenocarcinoma of the rectum
• • 2. Tumor located within 12cm of anal verge
• • 3. Clinical stage of cT3-4Nany (cStage II) or cTanyN1-2 (cStage III) by rectal MRI
• • 4. Available tumor samples for methylation-specific PCR (MSP) to investigate MGMT hypermethylation
• • 5. Male or female aged over 20 years
• • 6. Be ambulatory and have an Eastern Cooperative Oncology Group (ECOG) performance status0-1.
• • 7. No prior systemic treatment (chemotherapy, immunotherapy) or radiation therapy
• 8. Adequate major organ functions as following:
• • Hematopoietic function: ANC 1,500/mm3, Platelet 100,000/mm3 Hepatic function: serum bilirubin 2.0 mg/dL, AST/ALT levels 2.5 x UNL Renal function: serum creatinine UNL or Cockroft creatinine clearance 50 ml/min
• • 9. Be willing and able to comply with the protocol for the duration of the study.
• • 10. Give written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
• Exclusion Criteria:
• - Patients will be exluded from the study for any of the following reasons:
• • 1. Histology other than adenocarcinoma or tumor arising from inflammatory bowel disease
• • 2. Inadequate tumor sample for MGMT MSP
• • 3. Any evidence of systemic metastasis
• • 4. Unresected synchronous colon cancer; endoscopically resected synchronous colon cancer of pTis or pT1 is permitted
• • 5. Subjects unable to swallow oral medication because of such as current or impending intestinal obstructions, but bypass surgery (colostomy or ileostomy) is permitted before study treatment
• 6. Uncontrolled or severe cardiovascular disease:
• • New York Heart Association class III or IV heart disease.
• • Unstable angina or myocardial infarction within the past 6 months.
• • History of significant ventricular arrhythmia requiring medication with antiarrhythmics or significant conduction system abnormality.
• • 7. Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy.
• • 8. Other malignancy within the past 5 years except cured non-melanomatous skin cancer, carcinoma in situ of the cervix, or thyroid papillary carcinoma.
• • 9. Organ allografts requiring immunosuppressive therapy.
• • 10. Psychiatric disorder or uncontrolled seizure that would preclude compliance.
• • 11. Pregnant, nursing women or patients with reproductive potential without contraception.
• • 12. Patients receiving a concomitant treatment with drugs interacting with 5-FU such as flucytosine, phenytoin, or warfarin et al.
• • 13. Known dihydropyrimidine dehydrogenase (DPD) deficiency.
• • 14. Known hypersensitivity to any of the components of the study medications.